Q-omics provides the consensus-scored ZNF683 profile across patient tissues and cancer cell-line models. ZNF683 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ZNF683 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, ZNF683 RNA expression shows 10,260 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight SKCM, KIRC, and LIHC as cancer lineages where ZNF683 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF683 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF683 survival associations across molecular data types. ZNF683 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF683 RNA expression–survival associations across cancer types. High ZNF683 expression shows unfavorable associations in LGG and UVM, but favorable associations in SKCM, BLCA, UCEC and HNSC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ZNF683 RNA expression.
This table summarizes ZNF683 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF683. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF683 shows lower tumor expression in LUSC and PRAD and higher tumor expression in KIRC, KIRP, KICH and LIHC. The KIRC box plot shows higher ZNF683 RNA expression in tumor versus normal tissue (log2 FC = +1.618, t-test p < 0.001).
This table shows molecular features associated with ZNF683 in patient tissues and cancer cell lines. In patient samples, ZNF683 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF683 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
